Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.ncbi.nlm.nih.gov › pmc › articlesMemantine for the Treatment of Dementia: A Review on its Current...

   www.ncbi.nlm.nih.gov › pmc › articles

   13 mar 2018 · Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors.

2. www.ncbi.nlm.nih.gov › pmc › articlesBasic information about memantine and its treatment of...

   www.ncbi.nlm.nih.gov › pmc › articles

   6 cze 2023 · Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world.

3. www.ncbi.nlm.nih.gov › pmc › articlesMemantine: efficacy and safety in mild-to-severe Alzheimer’s...

   www.ncbi.nlm.nih.gov › pmc › articles

   2 mar 2007 · Memantine, an NMDA receptor antagonist has been found to be effective, both as monotherapy and in combination with donepezil, in the treatment of patients with moderate to severe stage AD.

4. pubmed.ncbi.nlm.nih.gov › 29254093Memantine for the Treatment of Dementia: A Review on its ... -...

   pubmed.ncbi.nlm.nih.gov › 29254093

   Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors. It has been demonstrated that MEM preferentially prevents the excessive continuous extrasynaptic NMDAR disease activation and therefore prevents neuronal cell death induced by excitotoxicity without ...

5. www.nejm.org › doi › fullDonepezil and Memantine for Moderate-to-Severe Alzheimer's...

   www.nejm.org › doi › full

   8 mar 2012 · Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

6. link.springer.com › referenceworkentry › 10Memantine for Treatment of Dementia | SpringerLink

   link.springer.com › referenceworkentry › 10

   • Zapisane w pamięci cache

   5 lis 2022 · The N-methyl-D-Aspartate receptor antagonist memantine with its less popular monoamine reuptake-inhibiting properties provides beneficial effects in patients with advanced Alzheimer’s disease on an acetylcholine esterase inhibitor treatment regimen.

7. www.uptodate.com › contents › 5072Cholinesterase inhibitors in the treatment of dementia

   www.uptodate.com › contents › 5072

   • Zapisane w pamięci cache

   28 maj 2024 · Cholinesterase inhibitors and memantine are the only currently available symptomatic medications for cognition and global functioning in patients with dementia. Cholinesterase inhibitors target the acetylcholine deficit arising from loss of neurons in the nucleus basalis of Meynert and its projections in patients with dementia.